000126728 001__ 126728
000126728 005__ 20240228140843.0
000126728 0247_ $$2doi$$a10.1007/s00330-014-3458-5
000126728 0247_ $$2pmid$$apmid:25358594
000126728 0247_ $$2ISSN$$a0938-7994
000126728 0247_ $$2ISSN$$a1432-1084
000126728 0247_ $$2ISSN$$a1613-3749
000126728 0247_ $$2ISSN$$a1613-3757
000126728 0247_ $$2altmetric$$aaltmetric:3613975
000126728 037__ $$aDKFZ-2017-02756
000126728 041__ $$aeng
000126728 082__ $$a610
000126728 1001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b0$$eFirst author$$udkfz
000126728 245__ $$aThe application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken.
000126728 260__ $$aBerlin$$bSpringer$$c2015
000126728 3367_ $$2DRIVER$$aarticle
000126728 3367_ $$2DataCite$$aOutput Types/Journal article
000126728 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522156113_18537
000126728 3367_ $$2BibTeX$$aARTICLE
000126728 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126728 3367_ $$00$$2EndNote$$aJournal Article
000126728 520__ $$aThe current analysis investigated the prognostic significance of gadopentetate dimeglumine on survival and renal function in patients with monoclonal plasma cell disorders.In this study 263 patients who had received gadopentetate dimeglumine within a prospective trial investigating dynamic contrast-enhanced magnetic resonance imaging (MRI) were compared with 335 patients who had undergone routine, unenhanced MRI.We found no significant prognostic impact of the application of contrast agent on progression-free survival in patients with either monoclonal gammopathy of undetermined significance, smouldering or symptomatic myeloma and no significant prognostic impact on overall survival in patients with symptomatic myeloma. Since renal impairment is a frequent complication of myeloma, and decreased renal function is associated with a higher risk of complications in patients receiving contrast agents, we evaluated the impact of contrast agent on renal function after 1 year. In the present analysis the only significant adverse impact on kidney function occurred in symptomatic myeloma patients who already had impaired renal parameters at baseline. Here, the renal function did not recover during therapy, whereas it did so in patients with normal or only slightly impaired renal function.If general recommendations are adhered to, gadopentetate dimeglumine can be safely applied in patients with monoclonal plasma cell disease.
000126728 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000126728 588__ $$aDataset connected to CrossRef, PubMed,
000126728 650_7 $$2NLM Chemicals$$aContrast Media
000126728 650_7 $$0K2I13DR72L$$2NLM Chemicals$$aGadolinium DTPA
000126728 7001_ $$aStoll, J.$$b1
000126728 7001_ $$aZechmann, C. M.$$b2
000126728 7001_ $$0P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aKunz, C.$$b3$$udkfz
000126728 7001_ $$aWagner, B.$$b4
000126728 7001_ $$0P:(DE-HGF)0$$aHeiss, C.$$b5
000126728 7001_ $$aSumkauskaite, M.$$b6
000126728 7001_ $$aMoehler, T. M.$$b7
000126728 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, H. P.$$b8$$udkfz
000126728 7001_ $$aGoldschmidt, H.$$b9
000126728 7001_ $$0P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDelorme, Stefan$$b10$$eLast author$$udkfz
000126728 773__ $$0PERI:(DE-600)1472718-3$$a10.1007/s00330-014-3458-5$$gVol. 25, no. 3, p. 745 - 750$$n3$$p745 - 750$$tEuropean radiology$$v25$$x1432-1084$$y2015
000126728 909CO $$ooai:inrepo02.dkfz.de:126728$$pVDB
000126728 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000126728 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000126728 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000126728 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000126728 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000126728 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000126728 9141_ $$y2015
000126728 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000126728 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR RADIOL : 2015
000126728 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126728 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126728 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126728 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000126728 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000126728 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126728 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000126728 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126728 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126728 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000126728 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000126728 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x0
000126728 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000126728 980__ $$ajournal
000126728 980__ $$aVDB
000126728 980__ $$aI:(DE-He78)E010-20160331
000126728 980__ $$aI:(DE-He78)C060-20160331
000126728 980__ $$aUNRESTRICTED